Changing concepts of treatment in acute leukemia.
D000208:Acute Disease; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D002454:Cell Differentiation; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D004920:Erythropoiesis; D006410:Hematopoiesis; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007700:Kinetics; D007938:Leukemia / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control; D007942:Leukemia, Experimental / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D051379:Mice; D008938:Mitosis; D008954:Models, Biological; D009858:Oncogenic Viruses; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013997:Time Factors
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D003561:Cytarabine; D004247:DNA; D001215:Asparaginase; D011241:Prednisone